Health Care Deal News, October 6, 2014 - Top 10 Health Care Deals in Q3:14
Brought to you by www.DealSearchOnline.com
|Recent Health Care M&A Deals|
|Harvard Bioscience, Inc.||Multi Channel Systems MCS GmbH and Triangle BioSystems, Inc.||$11 million|
|ReproCELL||Stem Cell Reagent and Services business unit||$8.5 million|
|Laborie Medical Technologies, Inc.||Unisensor AG and Unisensor USA, Inc.||N/A|
|Zimmer Holdings, Inc.||ETEX Holdings, Incorporated||N/A|
Lumara Health Beats Bankruptcy, Finds Two Buyers
Lumara Health, formerly the K-V Pharmaceutical Company and Ther-Rx Corporation until it emerged from bankruptcy last May, is being sold in two transactions. Its flagship product line, the maternal health division, is going to specialty pharma company AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) for $675 million. Of that total, $600 million is in cash and 3,209,971 in newly issued shares of AMAG, plus additional consideration of up to $350 million based on achievement of certain sales milestones. Lumara’s women’s health business is going to Perrigo Company plc (NYSE: PRGO) for $82 million, presumably all cash. Perrigo can afford it.
Top 10 Health Care Deals in Q3:14
We’re tallying up all the deals and the prices announced in the third quarter of 2014. Preliminary totals show the most recent quarter posted 322 deals, for a record total of $116.8 billion. The total would have set a new record for third-quarter healthcare transactions, that is, until Salix Pharmaceuticals (NASDAQ: SLXP) pulled the plug on its $2.7 billion bid for Cosmo Technologies Ltd. (SIX: COPN), based in Dublin, last Friday. The record for third-quarter totals is still $118.3 billion, set in Q3:2011. Check out the chart for the top deals in Q3:14, and get all the figures in the October issue of Health Care M&A News.
Top 10 Health Care Deals in Q3:2014
|AbbVie||Shire plc||$54.7 billion|
|Roche||InterMune Inc.||$8.3 billion|
|Mylan, Inc.||Abbott's non-US generics business||$5.3 billion|
|NorthStar Realty||Griffin-American Healthcare REIT||$4.0 billion|
|Meda AB||Rottapharm S.p.A.||$3.05 billion|
|Cognizant Technology||TriZetto Corporation||$2.7 billion|
|Danaher Corp.||Nobel Biocare Holding AG||$2.2 billion|
|Johnson & Johnson||Alios BioPharma Inc.||$1.75 billion|
|Cerner Corp.||Siemens Health Services||$1.3 billion|
Source: The Health Care M&A Information Source, October 3, 2014
Sabra Health Care Bets on Independent Living Communities
Just in time for the annual NIC conference, Sabra Health Care REIT, Inc. (NASDAQ: SBRA) acquired 21 independent living communities from Holiday Retirement Corporation for $550 million. The communities are spread across 15 states, and have a total of 2,850 independent living units. The acquisition decreases Sabra’s Genesis concentration from 47% to 38%, and impacts its exposure to skilled nursing and transitional care facilities from 69% to 56%.
Cognoptix Raises Over $15 Million for Early-Stage Alzheimer's Test
Cognoptix, a medical device company based in Acton, Massachusetts, closed the first tranche of a Series D round of financing totaling over $15 million. The round was co-led by new investor Alopexx and existing investor Inventages, with participation from original investor, Launchpad Venture Group. The goal is to fund a pivotal trial for the company’s Sapphire II eye test designed to identify Alzheimer’s disease via a beta-amyloid signature in their eyes. The Series D investment will also fund the final stages of product development, and allow the company to complete the FDA registration process......Click here for a free trial to The Health Care M&A Information Source and download the current issue today.